Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.73 |
| ▸ | ACHE | P22303 | 3/20 | 0.73 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.73 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | ESR1 | P03372 | 2/20 | 0.73 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.62 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kushenol N SCHEMBL30451391 | 1.00 | BACE1 (0.73) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kushenol N SCHEMBL27013512 | 1.00 | BACE1 (0.73) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kushenol N SCHEMBL564568 | 1.00 | BACE1 (0.73) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kushenol N SCHEMBL27013513 | 1.00 | BACE1 (0.73) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kushenol X SCHEMBL4809925 | 0.91 | BACE1 (0.72) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kushenol K SCHEMBL27013479 | 0.87 | BACE1 (0.72) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kushenol K SCHEMBL564142 | 0.87 | BACE1 (0.72) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| SCHEMBL564482 | 0.86 | BACE1 (0.57) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kurarinone SCHEMBL10307529 | 0.84 | BACE1 (1.00) | BACE1ACHESLC5A1SLC5A2PTGS1 | |
| Kurarinone SCHEMBL12942466 | 0.84 | BACE1 (1.00) | BACE1ACHESLC5A1SLC5A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1348762-A | Application of kusheng (sophora Flavescences) flavone in preparing hypoglycemic | LUZHOU BAOGUANG PHARMACEUTICAL (CN) | 2002-05-15 | — | — | CN | claimed |
| US-10744219-B2 | Air freshener composition and preparation method thereof | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200164096-A1 | AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREOF | Guorun Biotechnology (Shenzhen) Co., Ltd. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3388137-B1 | AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREFOR | WANG JINGNING (CN) | 2020-04-15 | — | — | EP | disclosed |
| EP-3388137-A1 | AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREFOR | Wang, Jingning (CN) | 2018-10-17 | — | — | EP | disclosed |
| CN-102908341-A | Vitexicarpin used as pharmaceutical active ingredient with anti-angiogenesis function | UNIV TSINGHUA | 2013-02-06 | — | — | CN | disclosed |
| CN-102030812-B | Timosaponin A-III serving as medicinal active ingredient with angiogenesis resistance | UNIV TSINGHUA | 2012-07-04 | — | — | CN | disclosed |
| US-20120035855-A1 | METHOD OF NETWORK-BASED IDENTIFICATION FOR DRUG ACTION AND/OR SYNERGY EFFECT OF MEDICINE COMBINATION | TSINGHUA UNIVERSITY | 2012-02-09 | — | — | US | disclosed |
| EP-2369493-A1 | GENE NETWORK-BASED METHOD FOR CONFIRMING DRUG ACTION | Tsinghua University (CN) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010066150-A9 | GENE NETWORK-BASED METHOD FOR CONFIRMING DRUG ACTION | 清华大学 (CN) | 2011-07-21 | — | — | WO | disclosed |
| CN-102030812-A | Timosaponin A-III serving as medicinal active ingredient with angiogenesis resistance | UNIV TSINGHUA | 2011-04-27 | — | — | CN | disclosed |
| WO-2007126259-A1 | COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE CONTAINING EXTRACTS OF SOPHORA FLAVESCENS | PURIMED CO., LTD. (KR) | 2007-11-08 | — | — | WO | disclosed |
| WO-2006057893-A2 | COMPOSITION, DELIVERY SYSTEM AND METHOD FOR PROMOTING HEALTHY SEXUAL FUNCTION | MCCLEARY EDWARD LARRY (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060110477-A1 | Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | MCCLEARY EDWARD L | 2006-05-25 | — | — | US | disclosed |
| US-20060110478-A1 | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | MCCLEARY EDWARD L | 2006-05-25 | — | — | US | disclosed |
| CN-1348762-A | Application of kusheng (sophora Flavescences) flavone in preparing hypoglycemic | LUZHOU BAOGUANG PHARMACEUTICAL (CN) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060110478-A1 | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | PDE5A, PDE2A, SLC25A20 | BACE1 3695/4885ACHE 75/4885SLC5A1 1193/4885 |
| US-20060110477-A1 | Composition and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction | SHBG, KYNU, SLC25A20 | BACE1 2579/4885ACHE 366/4885SLC5A1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.